Click here to view this email in your browser INVITATIONMedicon Valley Alliance are pleased to invite you to an exclusive Good Morning Meeting hosted by Theradex Oncology and Simsen Diagnostics on 18h of November 2025.Designed specifically for pharmaceutical companies developing cancer therapi
 ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌   ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌   ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌   ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌   ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 
 ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌   ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌   ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌   ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌   ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

Click here to view this email in your browser

INVITATION

Medicon Valley Alliance are pleased to invite you to an exclusive Good Morning Meeting hosted by Theradex Oncology and Simsen Diagnostics on 18h of November 2025.


Designed specifically for pharmaceutical companies developing cancer therapies, this gathering offers an opportunity to gain actionable insights and explore innovative solutions for oncology clinical trials. Sharing the latest strategies for designing effective oncology studies, as well as actionable approaches for incorporating personalised, tumour-informed ctDNA analysis to enhance patient selection, monitoring, and trial outcomes, this event will equip you with practical knowledge to drive success in your oncology studies.



Why Attend?


- Gain practical strategies for developing clinical trials that maximise value from early design through to execution.


- Discover the impact of personalised ctDNA solutions, including improved patient selection, trial monitoring, and endpoint assessment.


- Engage in an interactive Q&A and discussions with industry experts and peers, addressing the specific challenges faced by small/medium sized oncology companies.


- Network with like-minded professionals.


Spaces are limited, so don’t miss this opportunity to connect, learn, and collaborate. Register now to secure your place and take the next step towards advancing your oncology clinical trials.


We look forward to welcoming you to Oncology Horizons Breakfast Meeting in Copenhagen!



Date: Tuesday, 18th November 2025

Time: 8:30 - 11:00
Venue: Medicon Valley Alliance, Arne Jacobsens Allé 15, 2300 Copenhagen S, Denmark - Auditorium, Hub2

SIGN UP

 

Program

8:30

Networking, registration and light breakfast

9:00

Welcome

David Munis Zepernick, Director, Member Engagement and Communication, Medicon Valley Alliance

9:05

Welcome & Opening Remarks

Joint introduction from Theradex and Simsen Diagnostics. Overview of the morning, aims, and relevance for small and medium-sized oncology companies.


9:15

Session 1: Setting Up Your Value-Generating Clinical Strategy

Presented by Theradex


Foundations of a robust clinical trial strategy

Key considerations for smaller oncology companies

Building value from early trial design to execution

9:35

Session 2: Personalised ctDNA Solutions for Clinical Trials

Presented by Simsen Diagnostics


The power of tumour-informed ctDNA in trial design

Enhancing patient selection, monitoring, and endpoints

Practical steps for integrating ctDNA analysis into your studies

9:55

Interactive Q&A and Roundtable Discussion


Open floor for questions, sharing of experiences, and exploring solutions to current challenges in oncology trials.

10:10

Closing Remarks & Next Steps


Summary of key takeaways, contact opportunities, and invitations for follow-up meetings.


10:15

Networking

11:00

End of Good Morning Meeting



Speakers


Stefan Filges, Chief Technology Officer at Simsen Diagnostics


Stefan Filges serves as Chief Technology Officer at Simsen Diagnostics, where he leads technology development and innovation in the healthcare diagnostics sector. He holds a PhD from Sahlgrenska Academy at Gothenburg University, bringing deep academic research experience and scientific expertise to advancing diagnostic technologies.

Hans Rosen, Managing Director, Theradex Oncology


Since joining Theradex Oncology in 2019, Hans Rosén has been serving as the Managing Director for the company’s European operations. With a strong entrepreneurial background in the life sciences sector, he brings proven expertise in advancing cancer drug candidates, having successfully guided two from initial discovery through to first-in-human clinical trials. Before joining Theradex, Hans served as CEO for two publicly listed life science companies on the NASDAQ Stockholm stock exchange over a period of eight years.

 

Organized by

In collaboration with

 

linkedin logo
twitter logo
youtube logo
mva logo small
linkedin logo
twitter logo
youtube logo
mva logo small

Arne Jacobsens Allé 15, 2. 2300 København S

Click here to unsubscribe or to change your subscription preferences